Report of the Third Working Party of the British Hypertension Society

Total Page:16

File Type:pdf, Size:1020Kb

Report of the Third Working Party of the British Hypertension Society Journal of Human Hypertension (1999) 13, 569–592 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh BHS GUIDELINES Guidelines for management of hypertension: report of the third working party of the British Hypertension Society LE Ramsay, B Williams, GD Johnston, GA MacGregor, L Poston, JF Potter, NR Poulter and G Russell for the British Hypertension Society ¼ Use non-pharmacological measures in all hyperten- as first-line therapy for the majority of hypertensive sive and borderline hypertensive people. people. In the absence of compelling indications for ¼ Initiate antihypertensive drug therapy in people with beta-blockade, diuretics or long acting dihydropyrid- sustained systolic blood pressures (BP) у160 mm Hg ine calcium antagonists are preferred to beta-blockers or sustained diastolic BP у100 mm Hg. in older subjects. Compelling indications and contra- ¼ Decide on treatment in people with sustained systolic indications for all antihypertensive drug classes are BP between 140 and 159 mm Hg or sustained diastolic specified. BP between 90 and 99 mm Hg according to the pres- ¼ For most hypertensives, a combination of antihyper- ence or absence of target organ damage, cardio- tensive drugs will be required to achieve the rec- vascular disease or a 10-year coronary heart disease ommended targets for blood pressure control. у (CHD) risk of 15% according to the Joint British ¼ Other drugs that reduce cardiovascular risk must also Societies CHD risk assessment programme/risk chart. be considered. These include aspirin for secondary ¼ In people with diabetes mellitus, initiate antihyperten- у prevention of cardiovascular disease, and primary sive drug therapy if systolic BP is sustained 140 prevention in treated hypertensive subjects over the mm Hg or diastolic BP is sustained у90 mm Hg. у ¼ age of 50 years who have a 10-year CHD risk 15% In non-diabetic hypertensive people, optimal BP treat- and in whom blood pressure is controlled to the audit ment targets are: systolic BP Ͻ140 mm Hg and dias- standard. In accordance with existing British rec- tolic BP Ͻ85 mm Hg. The minimum acceptable level of ommendations, statin therapy is recommended for control (Audit Standard) recommended is Ͻ150/Ͻ90 hypertensive people with a total cholesterol mm Hg. Despite best practice, these levels will be dif- у5 mmol/L and established vascular disease, or 10- ficult to achieve in some hypertensive people. у ¼ In diabetic hypertensive people, optimal BP targets year CHD risk 30% estimated from the Joint British are; systolic BP Ͻ140 mm Hg and diastolic BP Ͻ80 Societies CHD risk chart. Glycaemic control should mm Hg. The minimum acceptable level of control also be optimised in diabetic subjects. ¼ (Audit Standard) recommended is Ͻ140/Ͻ90 mm Hg. Specific advice is given on the management of hyper- Despite best practice, these levels will be difficult to tension in specific patient groups, ie, the elderly, achieve in some people with diabetes and hyperten- ethnic subgroups, diabetes mellitus, chronic renal sion. disease and in women (pregnancy, oral contraceptive ¼ In the absence of contraindications or compelling use and hormone replacement therapy). indications for other antihypertensive agents, low ¼ Suggestions for the implementation and audit of dose thiazide diuretics or beta-blockers are preferred these guidelines in primary care are provided. Keywords: BHS; management of hypertension Introduction patients3–7; treatment of isolated systolic hyperten- sion in the elderly8; comparison of the antihyperten- These guidelines update previous reports by work- sive efficacy and tolerability of different classes of ing parties of the British Hypertension Society in drug9–11; and the role of non-pharmacological meas- 1 2 1989 and 1993. Since the 1993 guidelines much ures in the prevention12–15 and treatment16 of hyper- new evidence has emerged, notably on optimal tension. There has been a vigorous debate about the blood pressure targets during antihypertensive treat- 17,18 3 safety of dihydropyridine calcium antagonists, ment ; management of hypertension in diabetic but also new evidence from randomised controlled trials for their efficacy and safety, particularly in iso- lated systolic hypertension in the elderly.8 These Correspondence: Professor Bryan Williams, Cardiovascular important additions to an already formidable body Research Institute, University of Leicester, Sir Robert Kilpatrick Building, PO Box 65, Leicester Royal Infirmary, Leicester LE2 of evidence are very welcome and provide the basis 7LX, UK for these new recommendations from the British Received and accepted 7 July 1999 Hypertension Society. Guidelines for management of hypertension British Hypertension Society 570 On the whole, physicians report that they adhered to previous recommendations by the British Hyper- BOX 1. Categories of Strength Used in Statements 19 (based on North of England evidence based guidelines, tension Society, but with some important excep- BMJ 1998)53 tions. They are less aware of, or less inclined to implement, recommendations to treat mild hyper- Strength of evidence tension and isolated systolic hypertension in the la-Evidence from meta-analysis of randomised controlled 19,20 trials elderly. National and international surveys con- Ib-Evidence from at least one randomised controlled trial tinue to reveal that there is under-diagnosis of IIa-Evidence from at least one controlled study without hypertension, that those diagnosed as hypertensive randomisation often do not continue on treatment, and that those IIb-Evidence from at least one other type of quasi- treated are often not controlled satisfactorily.21–23 experimental study III-Evidence from descriptive studies, such as The situation has improved in recent years but in comparative studies, correlation studies, and case- general the management of hypertension in the controlled studies United Kingdom remains suboptimal.23 IV-Evidence from expert committee reports or opinions Also disturbing is further evidence that conven- or clinical experience of respected authorities, or both tional management of hypertension leaves patients Strength of recommendation at an unacceptably high risk of cardiovascular com- A-Directly based on category I evidence plications and death, particularly from coronary B-Directly based on category II evidence or extrapolated heart disease (CHD) but also from stroke.24–29 In part recommendation from category I evidence this is a consequence of suboptimal blood pressure C-Directly based on category III evidence or extrapolated 30 recommendation from category I or II evidence control, but other factors are also important. In a D-Directly based on category IV evidence or extrapolated recent study, the persistent excess of CHD events in recommendation from category I, II or III evidence treated hypertensive subjects was predicted by three factors; (i) evidence of target organ damage before treatment, (ii) a history of cigarette smoking before treatment, and (iii) the serum cholesterol values Societies ‘Cardiac Risk Assessor’ computer pro- before and during treatment.29 These observations gramme. Consequently, whilst acknowledging that support the concept that effective management of CVD prevention is the proper focus of hypertension hypertension requires the identification of those at management, the levels of CHD risk quoted in these highest cardiovascular risk and the adoption of guidelines, appropriately precipitate intervention multifactorial intervention, targeting not only blood for those at higher CVD risk. pressure levels, but also associated cardiovascular These guidelines are intended for general prac- risk factors. These new guidelines embrace this con- titioners, practice nurses, and generalists in hospital cept and provide detailed guidance on the manage- practice, and aim to present as clearly as possible, ment of hypertension and associated cardiovascular the best currently available evidence on hyperten- risk factors. sion management. The evidence supporting the rec- The recent trials of statins31–34 and aspirin3,35 for ommendations contained in these new British the prevention of CHD are important steps forward Hypertension Society guidelines is graded using the for hypertension management since the previous North of England Group Criteria53 (Box 1). The guidelines. A significant proportion of hypertensive guidelines should be applied with due regard to patients will benefit from aspirin and statin treat- local circumstances and policies, and with appropri- ment, even if these treatments are only targeted at ate clinical judgement as regards the needs of indi- those with a high level of CHD risk.36,37 Formal esti- vidual patients (Box 2). mation of CHD risk has been proposed as an aid to 38–45 treatment decisions in hypertension, and Blood pressure measurement (Box 3) debated.46–49 This estimation ideally entails coun- ting and weighting major cardiovascular risk factors All adults should have blood pressure measured in addition to blood pressure itself.50 Mindful of the routinely at least every 5 years until the age of 80 strong relationship between blood pressure and the years. Those with high-normal values (135–139/85– risk of stroke, the Society acknowledges that tar- 89 mm Hg) and those who have had high readings geting cardiovascular disease risk (CVD) rather than at any time previously should have blood pressure CHD risk is preferable. However, in order to be con- re-measured annually. The British Hypertension sistent with
Recommended publications
  • Angiotensin-Converting Enzyme (ACE) Inhibitors Single Entity Agents
    Therapeutic Class Overview Angiotensin-Converting Enzyme (ACE) Inhibitors Single Entity Agents Therapeutic Class Overview/Summary: The renin-angiotensin-aldosterone system (RAAS) is the most important component in the homeostatic regulation of blood pressure.1,2 Excessive activity of the RAAS may lead to hypertension and disorders of fluid and electrolyte imbalance.3 Renin catalyzes the conversion of angiotensinogen to angiotensin I. Angiotensin I is then cleaved to angiotensin II by angiotensin- converting enzyme (ACE). Angiotensin II may also be generated through other pathways (angiotensin I convertase).1 Angiotensin II can increase blood pressure by direct vasoconstriction and through actions on the brain and autonomic nervous system.1,3 In addition, angiotensin II stimulates aldosterone synthesis from the adrenal cortex, leading to sodium and water reabsorption. Angiotensin II exerts other detrimental cardiovascular effects including ventricular hypertrophy, remodeling and myocyte apoptosis.1,2 The ACE inhibitors block the conversion of angiotensin I to angiotensin II, and also inhibit the breakdown of bradykinin, a potent vasodilator.4 Evidence-based guidelines recognize the important role that ACE inhibitors play in the treatment of hypertension and other cardiovascular and renal diseases. With the exception of Epaned® (enalapril solution) and Qbrelis® (lisinopril solution), all of the ACE inhibitors are available generically. Table 1. Current Medications Available in Therapeutic Class5-19 Generic Food and Drug Administration
    [Show full text]
  • Interaction of the Sympathetic Nervous System with Other Pressor Systems in Antihypertensive Therapy
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2001; 4 (3), 185-192 Interaction of the Sympathetic Nervous System with other Pressor Systems in Antihypertensive Therapy Wenzel RR, Baumgart D, Bruck H, Erbel R, Heemann U Mitchell A, Philipp Th, Schaefers RF Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria FOCUS ON SYMPATHETIC TONE Interaction of SNS J Clin Basic Cardiol 2001; 4: 185 Interaction of the Sympathetic Nervous System with Other Pressor Systems in Antihypertensive Therapy R. R. Wenzel1, H. Bruck1, A. Mitchell1, R. F. Schaefers1, D. Baumgart2, R. Erbel2, U. Heemann1, Th. Philipp1 Regulation of blood pressure homeostasis and cardiac function is importantly regulated by the sympathetic nervous system (SNS) and other pressor systems including the renin-angiotensin system (RAS) and the vascular endothelium. Increases in SNS activity increase mortality in patients with hypertension, coronary artery disease and congestive heart failure. This review summarizes some of the interactions between the main pressor systems, ie, the SNS, the RAS and the vascular endothelium including the endothelin-system. Different classes of cardiovascular drugs interfere differently with the SNS and the other pressor systems. Beta-blockers, ACE-inhibitors and diuretics have no major effect on central SNS activity. Pure vasodilators including nitrates, alpha-blockers and DHP-calcium channel blockers increase SNS activity. In contrast, central sympatholytic drugs including moxonidine re- duce SNS activity. The effects of angiotensin-II receptor antagonist on SNS activity in humans are not clear, experimental data are discussed in this review.
    [Show full text]
  • Beta-Blockers for Hypertension: Time to Call a Halt
    Journal of Human Hypertension (1998) 12, 807–810 1998 Stockton Press. All rights reserved 0950-9240/98 $12.00 http://www.stockton-press.co.uk/jhh FOR DEBATE Beta-blockers for hypertension: time to call a halt DG Beevers University Department of Medicine, City Hospital, Birmingham B18 7QH, UK Beta-blockers are not very effective at lowering blood the endorsement of beta-blockers by the British Hyper- pressure in elderly hypertensive patients or in Afro- tension Society and other guidelines committees, Caribbeans and these two groups represent a large pro- except possibly for severe resistant hypertension, high portion of people with raised blood pressure. Further- risk post-infarct patients and those with angina pectoris. more they do not prevent more heart attacks than the The time has come to move across to newer, safer, more thiazide diuretics. Beta-blockers can also be dangerous tolerable and more effective antihypertensive agents in many hypertensive patients and even when these whilst continuing to use thiazide diuretics in low doses drugs are not contraindicated, they cause subtle and in the elderly as first choice, providing there are no depressing side effects which should preclude their contraindications. usefulness. The time has come therefore to reconsider Keywords: beta-blockers; hypertension Introduction Safety and tolerability Beta-adrenergic blockers were first introduced in the There is little doubt that the beta-blockers are the early 1960s for the treatment of angina pectoris. most unsafe of all antihypertensive drugs. They can Their antihypertensive properties were not fully precipitate or worsen heart failure in patients with recognised until the celebrated paper by Pritchard myocardial damage and they are contraindicated in and Gillam in 1964.1 They rapidly became popular patients with asthma.
    [Show full text]
  • 3. Diuretics for Hypertension-A Review and Update
    REVIEW Diuretics for Hypertension: A Review and Update George C. Roush1 and Domenic A. Sica2 Downloaded from https://academic.oup.com/ajh/article-abstract/29/10/1130/2622231 by Xenia Agorogianni user on 17 July 2019 This review and update focuses on the clinical features of hydrochlo- ectopy and reduce the risk for sudden cardiac death relative to thi- rothiazide (HCTZ), the thiazide-like agents chlorthalidone (CTDN) and azide-type diuretics used alone. A recent synthesis of 44 trials has indapamide (INDAP), potassium-sparing ENaC inhibitors and aldos- shown that the relative potencies in milligrams among spironolac- terone receptor antagonists, and loop diuretics. Diuretics are the sec- tone (SPIR), amiloride, and eplerenone (EPLER) are approximately ond most commonly prescribed class of antihypertensive medication, from 25 to 10 to 100, respectively, which may be important when SPIR and thiazide-related diuretics have increased at a rate greater than is poorly tolerated. SPIR reduces proteinuria beyond that provided by that of antihypertensive medications as a whole. The latest hyper- other renin angiotensin aldosterone inhibitors. EPLER also reduces tension guidelines have underscored the importance of diuretics for proteinuria and has beneficial effects on endothelial function. While all patients, but particularly for those with salt-sensitive and resist- guidelines often do not differentiate among specific diuretics, this ant hypertension. HCTZ is 4.2–6.2 systolic mm Hg less potent than review demonstrates that these distinctions are important for man- CTDN, angiotensin-converting enzyme inhibitors, beta blockers, and aging hypertension. calcium channel blockers by 24-hour measurements and 5.1 mm Hg systolic less potent than INDAP by office measurements.
    [Show full text]
  • Calcium Channel Blockers
    Calcium Channel Blockers Summary In general, calcium channel blockers (CCBs) are used most often for the management of hypertension and angina. There are 2 classes of CCBs: the dihydropyridines (DHPs), which have greater selectivity for vascular smooth muscle cells than for cardiac myocytes, and the non-DHPs, which have greater selectivity for cardiac myocytes and are used for cardiac arrhythmias. The DHPs cause peripheral edema, headaches, and postural hypotension most commonly, all of which are due to the peripheral vasodilatory effects of the drugs in this class of CCBs. The non-DHPs are negative inotropes and chronotropes; they can cause bradycardia and depress AV node conduction, increasing the risk of heart failure exacerbation, bradycardia, and AV block. Clevidipine is a DHP calcium channel blocker administered via continuous IV infusion and used for rapid blood pressure reductions. All CCBs are substrates of CYP3A4, but both diltiazem and verapamil are also inhibitors of 3A4 and have an increased risk of drug interactions. Verapamil also inhibits CYP2C9, CYP2C19, and CYP1A2. Pharmacology CCBs selectively inhibit the voltage-gated L-type calcium channels on cardiac myocytes, vascular smooth muscle cells, and cells within the sinoatrial (SA) and atrioventricular (AV) nodes, preventing influx of extracellular calcium. CCBs act by either deforming the channels, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the major cellular calcium store, the endoplasmic reticulum. Calcium influx via these channels serves for excitation-contraction coupling and electrical discharge in the heart and vasculature. A decrease in intracellular calcium will result in inhibition of the contractile process of the myocardial smooth muscle cells, resulting in dilation of the coronary and peripheral arterial vasculature.
    [Show full text]
  • Information Presse an Antihypertensive Drug Improves Corticosteroid-Based Skin Treatments
    Paris, le 18 mars 2015 Information presse An antihypertensive drug improves corticosteroid-based skin treatments Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, “Cordeliers Research Centre”) to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases. This work is published in the Journal of Investigative Dermatology. Corticosteroid-based dermatological creams are indicated for the symptomatic treatment of inflammatory skin conditions, such as atopic dermatitis and psoriasis, for example. However, they have frequent side effects, such as a slight burning sensation, and very often end by inducing skin atrophy (thinning of the skin, which becomes fragile), which is inconvenient for the patient, and for which there is presently no treatment. The researchers from Inserm formulated a hypothesis whereby this harmful effect might be related to the inappropriate activation by these creams of mineralocorticoid receptors located in the epidermis. These receptors, which are present in the kidney, heart, eye, and certain neurons in particular, reacted with aldosterone, a hormone that regulates the blood pressure. Moreover, previous studies also showed them to be highly sensitive to corticosteroids. Application of corticosteroids to cultured skin causes it to become thinner: in 6 days, the thickness of the epidermis was reduced by one-third. The researchers then induced a pharmacological blockade of the receptors by adding specific antagonists to the corticosteroid treatment. The inability of the corticosteroid to bind to the mineralocorticoid receptors restores proliferation of the epidermal cells, and partially corrects epidermal atrophy. From the clinical point of view, it turns out that spironolactone, a drug used for a very long time as an antihypertensive drug (and which has marketing authorisation), is an antagonist of the mineralocorticoid receptor.
    [Show full text]
  • Study on Cognition and Prognosis in the Elderly (SCOPE)
    BLOOD PRESSURE 1999; 8: 177±183 Study on COgnition and Prognosis in the Elderly (SCOPE) L. HANSSON1, H. LITHELL1, I. SKOOG2, F. BARO3,C.M.BA´NKI4, M. BRETELER5, P. U. CARBONIN6, A. CASTAIGNE7, M. CORREIA8, J.-P. DEGAUTE9, D. ELMFELDT10, K. ENGEDAL11, C. FARSANG12, J. FERRO8, V. HACHINSKI13, A. HOFMAN5, O. F. W. JAMES14, E. KRISIN10, M. LEEMAN9, P. W. DE LEEUW15, D. LEYS16, A. LOBO17, G. NORDBY11, B. OLOFSSON10, G. OPOLSKI18, M. PRINCE19, F. M. REISCHIES20, J. B. ROSENFELD21, L. RUILOPE22, J. SALERNO23, R. TILVIS24, P. TRENKWALDER25 AND A. ZANCHETTI26 From 1Uppsala, 2Go¨teborg, Sweden, 3Bierbeek, Belgium, 4Nagyka´llo´, Hungary, 5Rotterdam, The Netherlands, 6Roma, Italy, 7Cre´teil, France, 8Lisboa, Portugal, 9Bruxelles, Belgium, 10Mo¨lndal, Sweden, 11Oslo, Norway, 12Budapest, Hungary, 13London, Ontario, Canada, 14Newcastle upon Tyne, UK, 15Maastricht, The Netherlands, 16Lille, France, 17Zaragoza, Spain, 18Warsaw, Poland, 19London, UK, 20Berlin, Germany, 21Tel-Aviv, Israel, 22Madrid, Spain, 23Washington DC, USA, 24Helsinki, Finland, 25Starnberg, Germany, 26Milan, Italy Hansson L, Lithell H, Skoog I, Baro F, Ba´nki CM, Breteler M, Carbonin PU, Castaigne A, Correia M, Degaute J-P, Elmfeldt D, Engedal K, Farsang C, Ferro J, Hachinski V, Hofman A, James OFW, Krisin E, Leeman M, De Leeuw PW, Leys D, Lobo A, Nordby G, Olofsson B, Opolski G, Prince M, Reischies FM, Rosenfeld JB, Ruilope L, Salerno J, Tilvis R, Trenkwalder P, Zanchetti A. Study on cognition and prognosis in the elderly (SCOPE). Blood Pressure 1999; 8: 177–183. The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multicentre, prospective, randomized, double-blind, parallel-group study designed to compare the effects of candesartan cilexetil and placebo in elderly patients with mild hypertension.
    [Show full text]
  • Antihypertensive Treatment in Kidney Transplant Recipients—A Current Single Center Experience
    Journal of Clinical Medicine Article Antihypertensive Treatment in Kidney Transplant Recipients—A Current Single Center Experience Ulrich Jehn 1 , Katharina Schütte-Nütgen 1, Markus Strauss 2, Jan Kunert 1, Hermann Pavenstädt 1, Gerold Thölking 1 , Barbara Suwelack 1 and Stefan Reuter 1,* 1 Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, 48149 Münster, Germany; [email protected] (U.J.); [email protected] (K.S.-N.); [email protected] (J.K.); [email protected] (H.P.); [email protected] (G.T.); [email protected] (B.S.) 2 Department of Medicine C, Division of Cardiology and Angiology, University Hospital of Münster, 48149 Münster, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-251-83-47540; Fax: +49-251-83-56973 Received: 16 October 2020; Accepted: 3 December 2020; Published: 7 December 2020 Abstract: Arterial hypertension affects the survival of the kidney graft and the cardiovascular morbidity and mortality of the recipient after kidney transplantation (KTx). Thus, antihypertensive treatment is necessary for a vast majority of these patients. Long-term data on antihypertensive drugs and their effects on allograft function after KTx is still limited, and further investigation is required. We retrospectively analyzed a cohort of 854 recipients who received a kidney transplant at our transplant center between 2007 and 2015 with regard to antihypertensive treatment and its influence on graft function and survival. 1-y after KTx, 95.3% patients were treated with antihypertensive therapy. Of these, 38.6% received mono- or dual-drug therapy, 38.0% received three to four drugs and 8.1% were on a regimen of 5 drugs.
    [Show full text]
  • JNC 7 Express the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    National High Blood Pressure Education Program JNC 7 Express The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute JNC 7 Express The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure This work was supported entirely by the National Heart, Lung, and Blood Institute. The Executive Committee, writing teams, and reviewers served as volunteers without remuneration. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute National High Blood Pressure Education Program NIH Publication No. 03-5233 December 2003 Chair Aram V. Chobanian, M.D. (Boston University Medical Center, Boston, MA) Executive Committee George L. Bakris, M.D. (Rush Presbyterian-St. Luke’s Medical Center, Chicago, IL); Henry R. Black, M.D. (Rush Presbyterian-St. Luke’s Medical Center, Chicago, IL); William C. Cushman, M.D. (Veterans Affairs Medical Center, Memphis, TN); Lee A. Green, M.D., M.P.H. (University of Michigan, Ann Arbor, MI); Joseph L. Izzo, Jr., M.D. (State University of New York at Buffalo School of Medicine, Buffalo, NY); Daniel W. Jones, M.D. (University of Mississippi Medical Center, Jackson, MS); Barry J. Materson, M.D., M.B.A. (University of Miami, Miami, FL); Suzanne Oparil, M.D. (University of Alabama at Birmingham, Birmingham, AL); Jackson T. Wright, Jr., M.D., Ph.D. (Case Western Reserve University, Cleveland, OH) Executive Secretary Edward J.
    [Show full text]
  • Effects of a New Calcium Channel Blocker, Azelnidipine, on Systemic Hemodynamics and Renal Sympathetic Nerve Activity in Spontaneously Hypertensive Rats
    1017 Hypertens Res Vol.28 (2005) No.12 p.1017-1023 Original Article Effects of a New Calcium Channel Blocker, Azelnidipine, on Systemic Hemodynamics and Renal Sympathetic Nerve Activity in Spontaneously Hypertensive Rats Takatomi SHOKOJI*, Yoshihide FUJISAWA**, Hideyasu KIYOMOTO***, Matlubur RAHMAN*,***, Guang-Ping SUN***, Yu-Yan FAN*, Shoji KIMURA*, Masakazu KOHNO***, Youichi ABE*, and Akira NISHIYAMA* Antihypertensive treatment with dihydropyridine calcium channel blockers elicits sympathetic nerve activa- tion, which may contribute to cardiovascular events. However, recent clinical studies showed that treatment with azelnidipine, a new dihydropyridine calcium channel blocker, significantly reduced blood pressure in hypertensive patients while either maintaining or actually decreasing heart rate (HR). In this study, we exam- ined the effects of azelnidipine and amlodipine on systemic hemodynamics and renal sympathetic nerve activity (RSNA) in anesthetized spontaneously hypertensive rats (SHR). We also examined the effects of these agents on baroreflex functions by infusing phenylephrine (30 µg/kg/min, i.v.) and sodium nitroprus- side (10 µg/kg/min, i.v.) into azelnidipine- or amlodipine-treated SHR. Fifty min after administration of azelni- dipine (10 µg/kg/min for 10 min, i.v.), mean arterial pressure (MAP) significantly decreased from 153±5 to 122±5 mmHg; however, HR and integrated RSNA did not change significantly (from 352±9 to 353±10 beats/ min and 115±5% of baseline, respectively). Infusion of amlodipine (50 µg/kg/min for 10 min) elicited similar effects on MAP (from 152±5 to 120±4 mmHg). However, amlodipine significantly increased HR (from 351±9 to 375±11 beats/min) and integrated RSNA (165±5% of baseline).
    [Show full text]
  • Calcium Channel Blockers in Hypertension: the Debate Reawakens
    Journal of Human Hypertension (2001) 15, 85–87 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh COMMENTARY Calcium channel blockers in hypertension: the debate reawakens GYH Lip and DG Beevers University Department of Medicine, City Hospital, Birmingham B18 7QH, UK Keywords: calcium channel blockers; meta-analysis; mortality; morbidity Ever since the publication of the Puget Sound phar- the confidence of any one study to be sure of these macosurveillance study in 1995,1 there has been a such differences.7,8 continuing debate on the effectiveness or safety of Then as the millennium year ground to its sodden the calcium channel blockers (CCBs) in the treat- halt (in England at least) came a ‘rush’ of meta- ment of hypertension and heart disease. Various analyses. To highlight a few, The Lancet published retrospective case-control studies had raised the two papers on 9 December9,10 and a ‘mini’ meta- possibility that these drugs may cause haemorrhage, analysis in their correspondence columns on 2nd suicide, cancer and excess cardiovascular morbidity December.11 Another appeared in the British Journal and mortality.2 Several observational studies and of Cardiology in November.12 There probably have some individual randomised trials in hypertension been many others. Perhaps meta-analyses begat have even suggested that, compared with other further meta-analyses. drugs, CCBs may be associated with a higher risk of The Blood Pressure Lowering Treatment Trialists’ coronary events, despite similar blood pressure
    [Show full text]
  • Antihypertensive Drug Use During Pregnancy: a Population Based Study
    236 Ann Ist Super Sanità 2015 | Vol. 51, No. 3: 236-243 DOI: 10.4415/ANN_15_03_12 Antihypertensive drug use during pregnancy: a population based study Carmen D’Amore1, Francesco Trotta2, Roberto Da Cas1, Carlo Zocchetti3, Alfredo Cocci4 1 REVIEWS and Giuseppe Traversa 1Reparto di Farmacoepidemiologia, Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della AND Salute, Istituto Superiore di Sanità, Rome, Italy 2Ufficio di Farmacovigilanza, Agenzia Italiana del Farmaco, Rome, Italy 3Unità di Programmazione Sanitaria, Direzione Generale Salute, Regione Lombardia, Milan, Italy 4Centro Regionale di Farmacovigilanza, Regione Lombardia, Milan, Italy ARTICLES RIGINAL Abstract Key words O Purpose. The study aimed at assessing if the European guideline on the use of antihyper- • antihypertensive drugs tensive drugs (AD) in pregnancy are followed in clinical practice. We also evaluated the • pregnancy association between the use of non-recommended drugs and individual characteristics. • clinical guidelines Methods. This study analyzed a cohort of 86 171 singleton deliveries occurring between 2009-2010 in the Lombardy region, Italy. Women with first prescription of AD during pregnancy were considered as incident users. Methyldopa, labetalol and nifedipine were considered as “recommended drugs”; all other AD were considered as “non-recommend- ed”. Odds Ratio and 95% confidence intervals were estimated. Results. Among the 1009 patients (1.2%) exposed to AD during pregnancy, 675 (66.9%) were incident users. Among the incident users, 31% received non-recommended drugs; this proportion decreased to 18% among women who started treatment in the third tri- mester. Women with at least four concomitant diseases had an elevated risk of receiving non-recommended drugs in pregnancy (OR 2.68; 95% CI 1.10-6.73).
    [Show full text]